<DOC>
	<DOCNO>NCT02569398</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment JNJ-54861911 slow cognitive decline compare placebo treatment , measure composite cognitive measure , Preclinical Alzheimer Cognitive Composite ( PACC ) , amyloid-positive participant asymptomatic risk develop Alzheimer 's dementia .</brief_summary>
	<brief_title>An Efficacy Safety Study JNJ-54861911 Participants Who Are Asymptomatic Risk Developing Alzheimer 's Dementia</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , multi-center ( one hospital medical school team work medical research study ) , placebo-controlled , parallel-group study participant asymptomatic risk develop Alzheimer 's dementia . The study consist Screening Phase ( approximately 90 day ) , treatment Phase ( 54 month ) follow-up Phase ( 7 28 day ) . In treatment Phase eligible Participants randomize receive study drug placebo daily 4.5 year . The maximum study duration participant 58 month . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Participant must global Clinical Dementia Rating Scale ( CDR ) score ' 0 ' Screening Participants 60 64 year age must also 1 follow 3 condition : ) positive family history dementia ( minimum 1 first degree relative ) , b ) previously know apolipoprotein E , ε4 allele ( APOE ɛ4 ) genotype , c ) previously know biomarker status demonstrate elevate amyloid accumulation cerebrospinal fluid ( CSF ) positron emission tomography ( PET ) Participant must able read write must adequate hear visual acuity complete psychometric test . The legally acceptable representative must also able read write Participants must evidence amyloid accumulation mean either : ) low Cerebrospinal Fluid ( CSF ) ABeta 142 level Screening ; b ) positive amyloid positron emission tomography ( PET ) scan Screening ( depend site 's PET capability ) visual read Participant must otherwise healthy age group medically stable without medication basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening Baseline Participant receive acetylcholinesterase ( AChE ) inhibitor and/or memantine time Screening Day 1 predose Participant evidence brain disease , potential early sign Alzheimer 's Dementia ( AD ) ( example . mild hippocampal atrophy ) typical agerelated change ( e.g . mild white matter hyperintensity magnetic resonance image [ MRI ] ) abnormality ( e.g . folic acid/Vitamin B12 deficiency ) could explain possible cognitive deficit ( include , limited vascular encephalopathy large stroke ( imaged cerebral MRI ) Participant contraindication MRI ( example , prosthesis , implant , claustrophobia , pacemaker ) Participant meet criterion dementia brain disorder cause dementia Participant evidence familial autosomal dominant AD ( mutation identify family and/or participant prior randomization )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>JNJ-54861911</keyword>
	<keyword>Dementia</keyword>
</DOC>